Partners for life

Abstract

Coming from a much respected industry that works hard and invests a lot of money in the development of new treatments that will save or improve lives, it is always frustrating to see that this good work and progress does not necessarily translate into increased share value. One can keep complaining that there is not enough money available to succeed in Europe - that investors don't support the biotech industry enough. The reality is that success and money will only come if biotech transforms its business model in order to meet investors' legitimate expectations of getting a reasonable return in a reasonable timeframe.